Free Trial
→ SpaceX eyes a 1.75 trillion valuation - here's what to know (From Brownstone Research) (Ad)tc pixel
NASDAQ:FHTX

Foghorn Therapeutics Q2 2024 Earnings Report

Foghorn Therapeutics logo
$4.44 +0.24 (+5.71%)
Closing price 04:00 PM Eastern
Extended Trading
$4.43 -0.01 (-0.11%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Foghorn Therapeutics EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.60
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Foghorn Therapeutics Revenue Results

Actual Revenue
$6.89 million
Expected Revenue
$6.60 million
Beat/Miss
Beat by +$290.00 thousand
YoY Revenue Growth
N/A

Foghorn Therapeutics Announcement Details

Quarter
Q2 2024
Date
8/8/2024
Time
Before Market Opens
Conference Call Date
Thursday, August 8, 2024
Conference Call Time
9:30AM ET

Upcoming Earnings

Foghorn Therapeutics' Q2 2026 earnings is estimated for Wednesday, May 13, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Foghorn Therapeutics' Q2 2024 Press ReleasePress Release
(8-K)
Foghorn Therapeutics' Q2 2024 Quarterly reportQuarterly report
(10-Q)

Foghorn Therapeutics Earnings Headlines

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
May 7 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3289817/0/en/foghorn-therapeutics-provides-first-quarter-2026-financial-and-corporate-update.html
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of "Moderate Buy" from Brokerages
May 5 at 4:10 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30759321
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
May 8 at 1:00 AM  |  Brownstone Research (Ad)
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/FHTX/pressreleases/36602402/foghorn-therapeutics-presents-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-for-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting/
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/21/3278403/0/en/foghorn-therapeutics-presents-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-for-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting.html
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
April 9, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/foghorn-therapeutics-to-present-new-preclinical-data-for-selective-smarca2-inhibitor-fhd-909-and-selective-cbp-ep300-and-arid1b-degrader-programs-at-the-2026-aacr-annual-meeting-1036006666
See More Foghorn Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Foghorn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Foghorn Therapeutics and other key companies, straight to your email.

About Foghorn Therapeutics

Foghorn Therapeutics (NASDAQ:FHTX) is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations. In addition to FHD-286, Foghorn maintains a pipeline of preclinical programs aimed at other chromatin targets, with the goal of advancing multiple development candidates into the clinic over the coming years.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics was established with support from leading life-science investors. The company operates research and development activities in the United States and collaborates with academic and industry partners to accelerate the translation of its discoveries into potential therapeutic options for patients worldwide.

Under the leadership of President and Chief Executive Officer Robert Mulroy, PhD, Foghorn has built a multidisciplinary team with expertise in epigenetics, medicinal chemistry, structural biology and translational medicine. The company’s strategic vision emphasizes innovation in chromatin biology and a commitment to developing differentiated treatments for oncology.

View Foghorn Therapeutics Profile
Earnings Tools